Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of intravenous AVE0005 (VEGF Trap) every 2 weeks in platinum- and erlotinib-resistant advanced or metastatic lung adenocarcinoma
2006-006144-55Phase 2Completed
- Sponsor
- Sanofi
- Start
- Feb 2007
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aflibercept in Non-small cell lung cancer adenocarcinoma (NSCLC), sponsored by Sanofi. Primary endpoint: Confirmed objective response rate. Started Feb 2007; status: completed.
02
Drugs
aflibercept
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on 2006-006144-55.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006144-55.